{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:28:27Z","timestamp":1793816907297,"version":"4.6.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have attracted interest as potential treatments for alcohol use disorder (AUD) after patients receiving these agents for obesity or type 2 diabetes reported a reduced desire to drink. This editorial examines whether current evidence supports their classification as broadly applicable addiction treatments or as phenotype-enriched therapies. Randomized trials evaluating exenatide and semaglutide suggest a clinically relevant but endpoint-selective signal. Reductions have been most consistent in heavy-drinking days, drinks per drinking day, naturalistic craving, alcohol-related consequences, and the World Health Organization (WHO) risk drinking level, whereas effects on total alcohol consumption, drinking frequency, and laboratory cue-elicited craving have been less consistent. Durable abstinence, sustained benefit after treatment discontinuation, prevention of alcohol-related hospitalization in randomized trials, and mortality benefit remain unestablished. Obesity may enrich treatment response and provide an independent metabolic indication, but current evidence neither identifies it as a necessary response biomarker nor establishes that alcohol reduction is mediated by weight loss. We therefore propose a three-axis clinical selection framework based on alcohol phenotype, metabolic phenotype, and treatment safety and feasibility. The strongest current rationale may be for patients with heavy episodic or loss-of-control drinking who also have obesity, type 2 diabetes, or substantial cardiometabolic risk. GLP-1 RAs should presently be regarded as candidate harm-reduction therapies that complement established AUD care, not as treatments for acute alcohol withdrawal or universal substitutes for approved pharmacotherapy. Larger comparative trials incorporating mechanistic outcomes and post-discontinuation follow-up are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005709","type":"journal-article","created":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:14Z","timestamp":1793815274000},"page":"6240-6243","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["When weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder"],"prefix":"10.1097","volume":"88","author":[{"given":"Sarah","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1683-2230","authenticated-orcid":false,"given":"Mehta","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kabul Medical University, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"395\u2013405","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"1687\u201398","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"636\u201345","DOI":"10.1176\/appi.ajp.20260003","article-title":"Oral semaglutide for alcohol use disorder: a randomized clinical trial","volume":"183","author":"Schacht","year":"2026","journal-title":"Am J Psychiatry"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"1246\u201354","DOI":"10.1001\/jamapsychiatry.2025.2508","article-title":"Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: a review","volume":"82","author":"Witkiewitz","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"E1364","DOI":"10.1503\/cmaj.230715","article-title":"Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder","volume":"195","author":"Wood","year":"2023","journal-title":"CMAJ"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"94\u201398","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:15Z","timestamp":1793815275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005709","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2026-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}